Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug
Summary: The highly lethal brain cancer glioblastoma (GBM) poses a daunting challenge because the blood-brain barrier renders potentially druggable amplified or mutated oncoproteins relatively inaccessible.Here, we identify sphingomyelin phosphodiesterase 1 (SMPD1), an enzyme mg09aca18te that regulates the conversion of sphingomyelin to ceramide, a